A Bayesian network meta-analysis (NMA) can help compare the various types of analgesics and anesthetics used for lowering pain of panretinal photocoagulation. We carried out a systematic review and network meta-analysis to assess pharmacological interventions for relieving pain in patients undergoing panretinal photocoagulation (PRP). We included 15 randomized controlled trials and 4 crossover trials with a total of 1787 eyes and 45.83 % of the participants were female. The mean age of the participants was 55 years. 2 % peribulbar lidocaine was the only significant treatment compared to placebo (MD -2.4 (95 % CrI -4.7 to -0.20). The rank probability and SUCRA also revealed 2 % peribulbar lidocaine (0.887) as the best treatment in terms of lowering the pain scores followed by etoricoxib (0.809) and potassium diclofenac (0.727). Two per cent peribulbar lidocaine is effective for reducing procedural pain in laser treatment compared to systemic and topical medications. Future studies should evaluate drugs that can reach and act on the posterior segment of the eye.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.survophthal.2025.01.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Updates on medical and surgical managements of diabetic retinopathy and maculopathy.
Asia Pac J Ophthalmol (Phila)
March 2025
The Primasia International Eye Research Institute (PIERI) of The Chinese University of Hong Kong (Shenzhen), Shenzhen, China; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR. Electronic address:
Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of vision loss globally. This is a comprehensive review focused on both medical and surgical management strategies for DR and DME. This review highlights the epidemiology of DR and DME, with a particular emphasis on the Asia-Pacific region, urban-rural disparities, ethnic variations, and grading methodologies.
View Article and Find Full Text PDFProliferative retinopathy in a patient with mutation in the gene.
Eur J Ophthalmol
February 2025
Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa, Israel.
Purpose: is a gene that encodes the voltage-gated chloride channel protein 2 in the human brain and eyes. While mutations in this gene have been associated with leukoencephalopathy as well as ocular manifestations including optic neuropathy and choroidopathy, here we report for the first time a case of severe proliferative retinopathy in a patient with mutation.
Observations: A 12-year-old girl with Familial Mediterranean Fever (FMF) was referred due to blurred vision in both eyes.
Development of Age-Related Macular Degeneration During Treatment for Diabetic Macular Edema: A Case Report.
Cureus
January 2025
Ophthalmology, Saitama Medical University, Iruma-gun, JPN.
We report a rare case of a patient who developed age-related macular degeneration (AMD) in one eye during treatment of diabetic macular edema (DME) in both eyes. A 70-year-old man was followed for diabetic retinopathy for 23 years. At his initial visit in 200X, his decimal visual acuity was 1.
View Article and Find Full Text PDFPharmacological therapy for relieving pain in panretinal photocoagulation: A network meta-analysis of randomized controlled trials.
Surv Ophthalmol
February 2025
University of Iowa, Iowa, IA, USA. Electronic address:
A Bayesian network meta-analysis (NMA) can help compare the various types of analgesics and anesthetics used for lowering pain of panretinal photocoagulation. We carried out a systematic review and network meta-analysis to assess pharmacological interventions for relieving pain in patients undergoing panretinal photocoagulation (PRP). We included 15 randomized controlled trials and 4 crossover trials with a total of 1787 eyes and 45.
View Article and Find Full Text PDFA Markov model assessing the cost-effectiveness of various anti-vascular endothelial growth factor drugs and panretinal photocoagulation for the treatment of proliferative diabetic retinopathy.
Eye (Lond)
February 2025
Science, Evidence and Analytics Directorate, National Institute for Health and Care Excellence, London, UK.
Background: Proliferative diabetic retinopathy (PDR) may lead to vision loss and blindness. The cost-effectiveness of various anti-vascular endothelial growth factor (anti-VEGF) drugs and panretinal photocoagulation (PRP) was assessed to supplement the NICE guideline for treating PDR.
Methods: A Markov model including eight levels of visual acuity (ranged between >85 and ≤25 letters) was developed to compare the cost-effectiveness of ranibizumab, aflibercept and bevacizumab with PRP (alone or in combination).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!